FAVRILLE REPORTS DATA FROM TRIAL OF FAVID AND RITUXAN

A A

Favrille has reported positive long-term follow-up data from its Phase II clinical trial of FavId following Rituxan treatment in patients with follicular B-cell non-Hodgkin's lymphoma (NHL).

In the study, administration of FavId following Rituxan appeared to improve response over Rituxan alone and extend time to disease progression compared to historical data. The data also compare favorably with previous immunotherapy studies in patients with B-cell NHL that have used chemotherapy to induce remissions.

A total of 103 patients were enrolled in the multicenter, open-label trial, of which 89 had stable disease or a better response to Rituxan and received FavId, including 55 who were relapsed from or refractory to prior treatments and 34 who were treatment-naive.